Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma
Lige Wu, Tongji Xie, Yan Li, Xuezhi Hao, Xin Zhang, Jianming Ying, Junling Li, Puyuan Xing · 2026
Read Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma by Lige Wu, Tongji Xie, Yan Li, Xuezhi Hao, Xin Zhang, Jianming Ying, Junling Li, Puyuan Xing (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13191858.txt.
Description
BackgroundThe efficacy of immune checkpoint inhibitor plus chemotherapy (ICI-chemo) following third-generation EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma (LUAD) is variable and lacks reliable predictive biomarkers. This study investigated associations between treatment-naïve primary tumor transcriptomic profiles, tumor immune microenvironment (TIME) characteristics, and subsequent ICI-chemo efficacy.MethodsThis retrospective study enrolled 12 advanced LUAD patients who received ICI-chemo after progressing on third-generation EGFR-TKIs.
Catalog record
| CREATOR | Lige Wu, Tongji Xie, Yan Li, Xuezhi Hao, Xin Zhang, Jianming Ying, Junling Li, Puyuan Xing |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |